IDH2 and acute myeloid leukemia: GA was more frequently identified in NPM1mut AML compared to the NPM1wt AML cohort, which included DNMT3A (39.2% vs. 12.6%; p < 0.0001), FLT3 (54.5% vs. 14.7%; p < 0.0001), IDH1 (16.1% vs. 5.6%; p < 0.0001), IDH2 (19.0% vs. 9.0%; p < 0.0001), TET2 (23.4% vs. 13.5%; p < 0.0001), PTPN11 (18.3% vs. 7.5%; p < 0.0001), WT1 (12.5% vs. 9.4%; p = 0.02), and CEBPA (8.2% vs. 6.4%; ns).